2008
DOI: 10.1002/14651858.cd005278.pub3
|Get access via publisher |Summarize |Cite
|
Sign up to set email alerts

Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis

Search citation statements

Order By: Relevance

Paper Sections

Select...
58
4
2
2

Citation Types

0
24
0
2

Year Published

Range
2009
2009
2025
2025

Publication Types

Select...
58
3
3

Relationship

1
63

Authors

Journals

citations

Cited by 63 publications

(26 citation statements)
references

References 37 publications

0
24
0
2
Order By: Relevance
How this paper cites the one you are viewing
“…The rate was higher despite the start of immunomodulatory treatment in 26.6% of our children with isolated ON. Such treatment was shown to decrease the rate of conversion to MS in adults with CIS and may have biased our results toward less MS cases compared to a natural history cohort . The use of more sensitive diagnostic criteria for MS in our cohort and a potential selection bias for MS versus non‐MS patients by an allowed shorter minimum follow‐up period for future MS patients may partially explain the difference to previous studies.…”
Section: Discussion
mentioning
confidence: 80%